Baseline matters: The importance of covariation for baseline severity in the analysis of clinical trials

American Journal of Drug and Alcohol Abuse

Volumn 37, Issue 5, 2011, Pages 446-452

  Nunes, Edward V ^a   Pavlicova, Martina ^b   Hu, Mei Chen ^a   Campbell, Aimee N ^a   Miele, Gloria ^a   Hien, Denise ^a,c   Klein, Donald F ^a,d  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b Columbia University ^*  (United States)

^c CITY UNIVERSITY OF NEW YORK   (United States)

^d NEW YORK UNIVERSITY   (United States)

Author keywords

Baseline severity; Clinical trials; Covariation; Interactions; Mental health

Indexed keywords

ADDICTION; ANALYSIS OF COVARIANCE; ARTICLE; CLINICAL TRIAL (TOPIC); COVARIANCE; DISEASE SEVERITY; EFFECT SIZE; HUMAN; INFECTION RISK; MEASUREMENT ERROR; OUTCOME ASSESSMENT; SEXUAL BEHAVIOR; SUBSTANCE ABUSE; THERAPY EFFECT;

EVIDENCE-BASED MEDICINE; HEALTH BEHAVIOR; HIV INFECTIONS; HUMANS; NATIONAL INSTITUTE ON DRUG ABUSE (U.S.); OUTCOME ASSESSMENT (HEALTH CARE); RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK-TAKING; SEVERITY OF ILLNESS INDEX; SUBSTANCE-RELATED DISORDERS; UNITED STATES;

EID: 80052210518     PISSN: 00952990     EISSN: 10979891     Source Type: Journal    
DOI: 10.3109/00952990.2011.596980     Document Type: Article

References (29)

1. Elkin I, Shea MT, Watkins JT, Imber SD, Sotsky SM, Collins JF, Glass DR, Pilkonis PA, LeberWR, Docherty JP, Fiester SJ, Parloff MB. National Institute of Mental Health Treatment of Depression Collaborative Research Program: General effectiveness of treatment. Arch Gen Psychiatry 1989; 46:971-982. (Pubitemid 19278225)
2. Klein DF, Ross DC. Reanalysis of the National Institute of Mental Health Treatment of Depression Collaborative Research Program General Effectiveness Report. Neuropsychopharmacology 1993; 8(3):241-251. (Pubitemid 23151392)
3. Fleiss JL. Appendix A: Sample-size determination. In Design and Analysis of Clinical Experiments. New York, NY: Wiley, 1986; 369-417.
4. Alterman AI, Kampman K, Boardman CR, Cacciola JS, Rutherford MJ, McKay JR, Maany I. A cocaine-positive baseline urine predicts outpatient treatment attrition and failure to attain initial abstinence. Drug Alcohol Depend 1997; 46:79-85. (Pubitemid 27323020)
5. Kampman KM, Volpicelli JR, Mulvaney F, Rukstalis M, Alterman AI, Pettinati H,Weinrieb RM, OBrien CP. Cocaine withdrawal severity and urine toxicology results from treatment entry predit outcome in medication trials for cocaine dependence. Addict Behav 2002; 27(2):251-260. (Pubitemid 34003038)
6. Bisaga A, Aharonovich E, Garawi F, Levin FF, Rubin E, Raby WN, Vosburg SK, Nunes EV. Utility of lead-in period in cocaine dependence pharmacotherapy trials. Drug Alcohol Depend 2005; 77(1):7-11. (Pubitemid 39656094)
7. Bisaga A, Aharonovich E, Garawi F, Levin FR, Rubin E, Raby WN, Nunes EV. A randomized placebo-controlled trial of gabapentin for cocaine dependence. Drug Alcohol Depend 2006; 81(3):267-274. (Pubitemid 43152453)
8. Garbutt JC, Kranzler HT, OMalley SS, Gastfriend DR, Pettinati HM, Silverman BL, Loewy JW, Ehrich EW. Vivitrex Study Group. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: A randomized controlled trial. J Am Med Assoc 2005; 293:1617-1625. (Pubitemid 40471792)
9. Stitzer ML, Petry N, Peirce J, Kirby K, Killeen T, Roll J, Hamilton J, Stabile PQ, Sterling R, Brown C, Kolodner K, Li R. Effectiveness of abstinence-based incentives: Interaction with intake stimulant test results. J Consult Clin Psychol 2007; 75:805-811. (Pubitemid 350052035)
10. Kampman KM, Pettinati H, Lynch KG, Dackis C, Sparkman T, Weigley C, OBrien CP. A pilot trial of topiramate for the treatment of cocaine dependence. Drug Alcohol Depend 2004; 75(3):233-240. (Pubitemid 38993293)
11. Kranzler HR, Burleson JA, Brown J, Babor TF. Fluoxetine treatment seems to reduce the beneficial effects of cognitivebehavioral therapy in type B alcoholics. Alcohol Clin Exp Res 1996; 20:1534-1541. (Pubitemid 26428102)
12. Pettinati HW, Volpicelli JR, Kranzler HR, Luck G, Rukstalis MR, Cnaan A. Sertraline treatment for alcohol dependence: Interactive effects of medication and alcohol subtype. Alcohol Clin Exp Res 2000; 24:1041-1049. (Pubitemid 30604324)
13. Brady KT, Sonne S, Anton RF, Randall CL, Back SE, Simpson K. Sertraline in the treatment of co-occurring alcohol dependence and posttraumatic stress disorder. Alcohol Clin Exp Res 2005; 29:395-401. (Pubitemid 40446132)
14. Najavits LM. Seeking Safety: A Treatment Manual for PTSD and Substance Abuse. New York, NY: Guilford, 2002.
15. Miller S, Pagan D, Tross SWomens health education. In Peer Activism for Female Partners of Injection Drug Users. New York, NY: Columbia University, 1998, Unpublished treatment manual.
16. Hien DA, Wells EA, Jiang H, Suarez-Morales L, Campbell AN, Cohen LR, Miele GM, Killeen T, Brigham GS, Zhang Y, Hansen C, Hodgkins C, Hatch-Maillette M, Brown C,Kulaga A, Kristman-Valente A, Chu M, Sage R, Robinson JA, Liu D, Nunes EV. Multi-site randomized trial of behavioral interventions for women with co-occurring PTSD and substance use disorders. J Consult Clin Psychol 2009; 77:607-619.
17. Hien DA, Campbell AN, Killeen T, Hu MC, Hansen C, Jiang H, Hatch-Maillette M, Miele GM, Cohen LR, Gan W, Resko SM, Dibono M, Wells EA, Nunes EV. The impact of traumafocused group therapy upon HIV sexual risk behaviors in the NIDA Clinical Trials Network "Women and trauma" multisite study. AIDS Behav 2010; 14(2):421-430.
18. Booth RE, Watters JK, Chitwood DD. HIV risk-related sex behaviors among injection drug users, crack smokers, and injection drug users who smoke crack. Am J Public Health 1993; 83:1144-1148. (Pubitemid 23229120)
19. Lambert D. Zero-inflated Poisson regression with an application to defects in manufacturing. Technometrics 1992; 34:1-14.
20. Pocock SJ, Assmann SE, Enos LE, Kasten LE. Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: Current practice and problems. Stat Med 2002; 21:2917-2930.
21. Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, Pitkin R, Rennie D, Schultz KF, Simel D, Stroup DF. Improving the quality of reporting of randomized controlled trials: The CONSORT statement. J Am Med Assoc 1996; 276:637-639. (Pubitemid 26278070)
22. Moher D, Schulz KF, Altman D, CONSORT Group. The CONSORT statement: Revised recommendations for improving the quality of reports of parallel-group randomized trials. J Am Med Assoc 2001; 285:1987-1991. (Pubitemid 32366951)
23. Schulz KF, Altman DG, Moher D, CONSORT Group. CONSORT 2010 statement: Updated guidelines for reporting parallel group randomized trials. BMJ 2010; 340:c332.
24. Moher D, Hopewell S, Schulz KF, Montori V, Gtzsche PC, Devereaux PJ, Elbourne D, Egger M, Altman DG, CONSORT Group. CONSORT 2010 explanation and elaboration: Updated guidelines for reporting parallel group randomized trials. BMJ 2010; 340:c869.
25. Assmann SF, Pocock SJ, Enos LE, Kasten LE. Subgroup analysis and other mis(uses) of baseline data in clinical trials. Lancet 2000; 355(9209):1064-1069. (Pubitemid 30162810)
26. Bhandari M, Devereaux PJ, Li P, Mah D, Lim K, Schnemann HJ, Tornetta P, III. Misuse of baseline comparison tests and subgroup analyses in surgical trials. Clin Orthop Relat Res 2006; 447:247-251. (Pubitemid 44324921)
27. Hernández AV, Steyerberg EW, Taylor GS, Marmarou A, Habbema JD, Maas AI. Subgroup analysis and covariate adjustment in randomized clinical trials of traumatic brain injury: A systematic review. Neurosurgery 2005; 57(6): 1244-1253. (Pubitemid 41827419)
28. Hernández AV, Boersma E,Murray GD, Habbema JD, Steyerberg EW. Subgroup analyses in therapeutic cardiovascular clinical trials: Are most of them misleading? Am Heart J 2006; 151(2):257-264. (Pubitemid 43148981)
29. Yusuf S, Wittes J, Probstfield J, Tyroler HA. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. J Am Med Assoc 1991; 266:93-98.